What question did this study set out to answer?

To validate and optimize a commercial assay for detecting nodo-paranodal antibodies in patients with CIDP.

February 22, 2026

Validation and optimisation of a commercial cell-based assay for detection of nodo-paranodal antibodies

Key Points

To validate and optimize a commercial assay for detecting nodo-paranodal antibodies in patients with CIDP.
Validation of a commercial cell-based assay
Assessment of autoantibodies against nodal structures
Optimization for improved detection
Autoantibodies identified in a subset of CIDP patients
Patients with these antibodies less likely to respond to IVIg treatment
B cell depletion shows greater effectiveness in patients with nodo-paranodal antibodies

Abstract

Introduction: A minority of patients satisfying diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have autoantibodies against components of nodal and paranodal structures in peripheral nerves. These patients are less likely to respond to intravenous immunoglobulin (IVIg) treatment and are more responsive to B cell depletion.

Demander à l'IA

Bookmark

Cite This Study

Leto et al. (Sun,) studied this question.

synapsesocial.com/papers/699a534bfdaf4e3c1268ee1f https://doi.org/https://doi.org/10.1016/j.pathol.2026.01.295

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark